Management of invasive cervical carcinoma in three oncology centers in Latin America: A historical cohort study

Peralta J.; Rodriguez J.; Acosta J.A.; Nuñez M.; Buitrago L.; Cetina L.; López A.; Cárdenas F.; Velásquez J.C. · International Journal of Gynecology and Obstetrics (2026) · DOI: 10.1002/ijgo.70371

Resumen

Objective: To describe clinical and sociodemographic characteristics of patients with invasive cervical cancer treated at three oncology centers in Latin America, as well as their risk factors, and management based on the FIGO stage 2009. Methods: This is a descriptive historical cohort study of patients with invasive cervical cancer recruited between January 2010 and June 2016. The study describes demographic characteristics, risk factors, treatments, and oncological outcomes at 1 and 5 years. Results: A total of 717 patients were included: 433 (60.39%) from INC Colombia, 174 (24.26%) from INCAN Mexico, and 110 (15.34%) from INEN Peru. Most patients were at FIGO Stage 2009 IIB 213 (29.70%), and the most common histologic subtype was squamous cell carcinoma 550 (76.71%). Concurrent chemo-radiotherapy was the most frequent approach 334 (46.48%), followed by surgical treatment 261 (36.40%) patients. Regarding oncological outcomes, the 5-year disease-free survival (DFS) for all patients was 76.72% (95% CI: 73.34%–80.18%), with worse outcomes observed for Stages III and IV compared to early stages. The 5-year overall survival (OS) for the general group was 83.76% (95% CI: 81.00%–86.73%), with statistically significant differences showing better outcomes for Stage I, with an OS of 94.52% (95% CI: 91.68–97.44). Conclusion: In this descriptive historical cohort, most patients received treatment according to their clinical stage. Survival rates, both overall and disease-free, were better for early-stage disease compared to advanced stages.